Author: Ren, Zhengxiao; Che, Ping; Li, Ziwei; Mo, Mei; Zhang, Shanshan; Zhang, Yingying
Title: [Progress in the relationship between NLRP3 inflammasome and lung injury in COVID-19]. Cord-id: 75urcz5i Document date: 2021_9_1
ID: 75urcz5i
Snippet: Severe inflammatory responses are considered responsible for acute lung damage in COVID-19. SARS-CoV-2 enters lung cells via ACE2, and the NLR family pyrin domain containing 3 (NLRP3) inflammasome and the pro-caspase-1 are then activated, followed by release of mature IL-1β and IL-18 and other inflammatory cytokines, thereby leading to inflammation and apoptosis. This inflammatory process induces syndromes such as inflammatory cell infiltration, congestion, and edema in the lungs of COVID-19 pa
Document: Severe inflammatory responses are considered responsible for acute lung damage in COVID-19. SARS-CoV-2 enters lung cells via ACE2, and the NLR family pyrin domain containing 3 (NLRP3) inflammasome and the pro-caspase-1 are then activated, followed by release of mature IL-1β and IL-18 and other inflammatory cytokines, thereby leading to inflammation and apoptosis. This inflammatory process induces syndromes such as inflammatory cell infiltration, congestion, and edema in the lungs of COVID-19 patients. Some severe cases reported complications including acute respiratory distress syndrome (ARDS) and diffuse intravascular coagulation (DIC). There is no specific drug available for the treatment of COVID-19 at present. MCC950, colchicine and other NLRP3 inflammasome inhibitors, have been widely used in the treatment of various inflammatory diseases, and are currently in clinical trials for the treatment of COVID-19 patients. Here we reviewed the pathogenesis of COVID-19 and the SARS-CoV activation pathway of NLRP3 inflammasome, in order to reveal the role and mechanism of NLRP3 inflammasome in the process of SARS-CoV-2 infection, and provide a theoretical basis for the development of related targeted drugs.
Search related documents:
Co phrase search for related documents- acute lung damage and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
Co phrase search for related documents, hyperlinks ordered by date